Modality
Fusion Protein
MOA
SHP2i
Target
PRMT5
Pathway
Angiogenesis
LGS
Development Pipeline
Preclinical
Aug 2022
→ Sep 2025
PreclinicalCurrent
NCT08960274
1,475 pts·LGS
2022-08→2025-09·Terminated
1,475 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-127mo agoInterim· LGS
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2025-09-12 · 7mo ago
LGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08960274 | Preclinical | LGS | Terminated | 1475 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET |